Furthermore, targeting at the inflammatory mediators in epilepsy, anti-IL-1, anti-IL-6, and anti-CD20 agents have been used in patients with drug-resistant epilepsy and refractory status epilepticus, with promising results and a good safety profile (Costagliola et al., 2022). The gene discussed is IL6; the disease is epilepsy.